CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 25 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-07-04 | Metzger Michael A President and COO | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2019-06-10 | Podlesak Dennis Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2019-06-10 | Meury William Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2019-06-10 | Legault Pierre Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2019-06-10 | Katkin Keith Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2019-06-10 | Jarrett Jennifer Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2019-06-10 | Egros Fabrice Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2019-05-13 | Morrison Briggs Chief Executive Officer | Purchase | +7,200 | $7.29 | $53K | 20,400 |
| 2019-05-09 | Morrison Briggs Chief Executive Officer | Purchase | +13,200 | $7.56 | $100K | 13,200 |
| 2019-03-21 | Meyers Michael L. SVP, Chief Medical Officer | Purchase | +8 | $4.87 | $39 | 7,230 |
| 2019-03-21 | Meyers Michael L. SVP, Chief Medical Officer | Purchase | +1,000 | $4.93 | $5K | 7,118 |
| 2019-03-21 | Meyers Michael L. SVP, Chief Medical Officer | Purchase | +104 | $4.87 | $506 | 7,222 |
| 2019-02-06 | Ordentlich Peter Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2019-02-06 | Morrison Briggs Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +354,000 | 354,000 | ||
| 2019-02-06 | Shea Richard P Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +91,200 | 91,200 | ||
| 2019-02-06 | Meyers Michael L. SVP, Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +104,325 | 104,325 | ||
| 2019-02-06 | Metzger Michael A President and COO | Grant or award · Stock Option (Right to Buy) | +240,000 | 240,000 | ||
| 2019-01-31 | Shea Richard P Chief Financial Officer | Other acquisition | +2,521 | $4.76 | $12K | 4,215 |
| 2019-01-31 | Meyers Michael L. SVP, Chief Medical Officer | Other acquisition | +3,720 | $4.76 | $18K | 6,118 |
| 2019-01-31 | Metzger Michael A President and COO | Other acquisition | +2,659 | $4.76 | $13K | 2,659 |
Page 23 of 25 · 500 trades